No Handa-cap as generic Seroquel licensee hits Par with US rights deal
This article was originally published in Scrip
After establishing itself as the first manufacturer with rights to market a generic version of AstraZeneca's Seroquel XR (quetiapine fumarate extended-release tablets) in the US, Handa Pharmaceuticals has entered into an acquisition and license agreement with Par Pharmaceutical that gives Par exclusive rights to Handa's abbreviated new drug application (ANDA) for the antipsychotic drug.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.